What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cholesterol
Internal medicine, Cardiology, Myocardial infarction, Cholesterol and Simvastatin are his primary areas of study.
His Internal medicine research incorporates themes from Placebo, Endocrinology and Surgery.
His work in Myocardial infarction tackles topics such as Diabetes mellitus which are related to areas like Retrospective cohort study, Heart failure and Framingham Risk Score.
His Cholesterol research incorporates elements of Statin, Blood pressure and Risk factor.
His work carried out in the field of Simvastatin brings together such families of science as Incidence, Survival rate, Ezetimibe/simvastatin, Vascular disease and Survival study.
His studies in Ezetimibe/simvastatin integrate themes in fields like Cholesterol absorption inhibitor, Lipid hypothesis, Pitavastatin, Pravastatin and Surrogate endpoint.
His most cited work include:
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) (8500 citations)
- Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. (2093 citations)
- Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) (1460 citations)
What are the main themes of his work throughout his whole career to date?
Anders G. Olsson focuses on Internal medicine, Cardiology, Endocrinology, Cholesterol and Simvastatin.
Anders G. Olsson regularly links together related areas like Placebo in his Internal medicine studies.
His study looks at the intersection of Cardiology and topics like Surgery with Risk factor.
Many of his studies involve connections with topics such as Gastroenterology and Endocrinology.
The concepts of his Cholesterol study are interwoven with issues in Statin and Disease.
The various areas that he examines in his Myocardial infarction study include Clinical endpoint and Hazard ratio.
He most often published in these fields:
- Internal medicine (68.86%)
- Cardiology (30.86%)
- Endocrinology (29.43%)
What were the highlights of his more recent work (between 2008-2021)?
- Internal medicine (68.86%)
- Cardiology (30.86%)
- Endocrinology (29.43%)
In recent papers he was focusing on the following fields of study:
Anders G. Olsson mainly investigates Internal medicine, Cardiology, Endocrinology, Cholesterol and Acute coronary syndrome.
His work in Lipoprotein, Myocardial infarction, Atorvastatin, Simvastatin and Apolipoprotein B is related to Internal medicine.
His Atorvastatin research includes elements of Pravastatin and Surrogate endpoint.
His work on Heart failure as part of general Cardiology study is frequently linked to In patient, therefore connecting diverse disciplines of science.
He combines subjects such as Statin, Disease and Pharmacology with his study of Cholesterol.
His Acute coronary syndrome study incorporates themes from Placebo, Adverse effect and Statin treatment.
Between 2008 and 2021, his most popular works were:
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (1421 citations)
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial (463 citations)
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial (398 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Surgery
His primary scientific interests are in Internal medicine, Myocardial infarction, Cardiology, Atorvastatin and Cholesterol.
His work on Endocrinology expands to the thematically related Internal medicine.
Anders G. Olsson mostly deals with Unstable angina in his studies of Myocardial infarction.
His Unstable angina study combines topics from a wide range of disciplines, such as Evacetrapib, Dalcetrapib and Cholesterylester transfer protein.
His study in Atorvastatin is interdisciplinary in nature, drawing from both Diabetes mellitus and Simvastatin.
His work deals with themes such as Tissue plasminogen activator and Risk factor, which intersect with Acute coronary syndrome.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
